and were prescribed to 3.6 % of patients in this study in 2008. Co-prescription of gastric protective therapy was made in 12-20 % of prescriptions with no differences between NSAID, Coxibs and non-NSAID. CONCLUSIONS: In this review of NSAID prescription utilization among patients with a diagnosis of musculoskeletal pain shows an extensive use of anti-inflammatory agents without co-prescription of gastro-protective medication. The impact of this high utilization of NSAIDs without co-prescription of gastroprotective agents on the risk for upper gastro-intestinal complications warrants further evaluation.
PSY55 IS HOSPITAL EXPERIENCE ASSOCIATED WITH BETTER IN-HOSPITAL OUTCOMES AMONG SICKLE CELL PATIENTS WITH ACUTE CHEST SYNDROME: RESULTS FROM A NATIONAL DATABASE
Kamble S, Reed SD Duke Clinical Research Institute, Durham, NC, USA OBJECTIVES: Acute chest syndrome (ACS) is the leading cause of death and the second most common cause of hospitalization in patients with sickle cell disease (SCD), yet it is unclear whether hospital experience (i.e., volume) is associated with improved clinical and resource-use outcomes. In this study, we compared inpatient mortality, length of stay (LOS) and total costs between high-and low-SCD volume hospitals treating ACS patients. METHODS: Using the 2006-2007 Nationwide Inpatient Sample (NIS), we identified ACS patients based on ICD-9-CM codes 517.3 (ACS) or 486 (pneumonia) among discharges with SCD (Clinical Classification Code 61). SCD volume represented the average number of SCD discharges from a hospital per year over the 2-year study period. Given that majority of patients were treated in a relatively small number of hospitals, the top decile was selected to represent high volume hospitals. We used generalized estimating equations to evaluate whether hospital-level SCD experience was independently associated with inpatient mortality (binomial distribution, logit link), LOS (negative binomial distribution, log link) and costs (gamma distribution, log link) between volume groups while controlling for gender, age, payer, number of comorbidities, and hospital characteristics, including rural vs. urban location, teaching status, bed size, ownership type, and hospital region. RESULTS: Among 6,857 ACS discharges across 688 hospitals, 4154 and 2703 were treated in high-and low-volume hospitals, respectively. Median age was 22 in highvolume hospitals and 29 in low-volume hospitals. In unadjusted analyses, inpatient mortality (0.9% vs. 1.7%, p = 0.004), mean LOS (6.9 vs. 7.4, p = 0.005), and mean costs ($11,358 vs. $12,013 , p = 0.077) were lower in high vs. low volume hospitals. After adjustment for patient and hospital characteristics, hospital volume was no longer significantly associated with inpatient outcomes. CONCLUSIONS: Hospital volume was not significantly associated with inpatient mortality, LOS, and total costs among ACS patients. 
PSY56 INFLIXIMAB INDUCTION PATTERNS AND THE IMPACT ON MAINTENANCE THERAPY PATTERNS

METHODS:
A retrospective analysis of medical claims from an administrative database was conducted for UC patients newly starting IFX. Patients were required to have age ≥18 yrs, 2 diagnosis codes for UC, IFX index date between September 1, 2005 and January 31, 2008, and ≥ 26 months of continuous enrollment (minimum 12 months before and 14 months after the index date). Patients with select pre-index inflammatory disorders were excluded. The analysis evaluated induction (IFX doses during first 56 days post-index) and maintenance (doses >56 days and <12 months post-induction). Persistence during maintenance was defined by a medication possession ratio (MPR) of >80%. Results were stratified by the number of induction doses (1, 2, or 3). RESULTS: A total of 354 UC patients were included in the analyses: mean (SD) age of 44 (14) yrs; 48.3% female; 62.4% received IFX in the outpatient office setting. There were 27, 83, and 244 patients in the 1, 2, and 3 induction dose groups, respectively. The overall mean (SD) number of days during the induction period was 35 (14) , and days increased with the number of induction doses. During the maintenance period, patients received an overall mean (median) of 5 (6) infusions. The cohort receiving 3 induction infusions had the highest percentage of patients with an MPR > 80%. Infusion patterns for the first year post-induction were consistent with recommended prescribing information, with a median of 56 days between infusions. CONCLUSIONS: The majority of IFX patients received 3 induction doses. Induction and maintenance infusion patterns were consistent with prescribing recommendations, especially for those patients receiving 3 induction doses. These data support administering 3 IFX doses during induction to ensure appropriate dosing and optimal medication adherence during maintenance. Minimal real world dosing data are available in this population. This study describes IFX dosing patterns in patients with CD treated in an outpatient hospital setting. METHODS: A retrospective longitudinal analysis using the Premier Perspective TM Database, a U.S.-based hospital database, was conducted. Inclusion criteria were an outpatient hospital discharge CD diagnosis between July 1, 2000 and March 31, 2008, IFX-naïve (received no IFX in the prior 180 days), and ≥ 3 IFX doses within ≤56 days of the index infusion. Exclusion criteria included patients with other selected inflammatory diseases. Treatment duration was defined as the time between the index and last IFX dose. Hospital outpatient dosing schedules were analyzed for the 4 th through 15 th IFX dose, representing the first two years of IFX maintenance treatment. RESULTS: A total of 1439 IFX-treated patients with CD were identified. Mean (SD) age was 42.8 (15.4) years; 59% were female. Mean (SD) treatment duration was 415 (425) days. Patients received a mean (SD) of 8.4 (7.5) IFX administrations. Mean (SD) index IFX dose was 429 (152) mg. During the initial two years of maintenance IFX administration, the highest observed mean IFX dose represented a 10% increase during the maintenance period and a 13% increase compared to the index IFX dose. Median time between administrations was 56 days for all maintenance infusions. CONCLUSIONS: The mean IFX dose remained between 439 and up to 483 mg throughout the maintenance treatment. Administration schedule was consistent with FDA-approved prescribing information. These data suggest that IFX dosing patterns in CD patients remain relatively stable with minimal dose escalation occurring when administered in real world outpatient hospital settings.
PSY57 MAINTENANCE INFLIXIMAB DOSING AND ADMINISTRATION PATTERNS IN PATIENTS WITH CROHN'S DISEASE
SYSTEMIC DISORDERS/CONDITIONS -Conceptual Papers & Research on Methods
PSY58 US COST EFFECTIVENESS ANALYSIS OF PRIMARY PROPHYLAXIS VERSUS ON-DEMAND TREATMENT IN HEMOPHILIA: DESIGN AND RATIONALE OF A COMPREHENSIVE MODEL
Boer R 1 , Lalla A 1 , Mathew P 2 , Preblick R 3 , Pocoski J 3 1 Cerner LifeSciences, Beverly Hills, CA, USA, 2 University of New Mexico, Albuquerque, NM, USA, 3 Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA OBJECTIVES: To present the design of a lifetime Markov model that compares the cost-effectiveness of primary prophylaxis versus on-demand treatment with recombinant factor VIII among children with severe hemophilia A. METHODS: Prophylactic infusions of rFVIII-FS have been shown to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no pre-existing joint damage. Clinical studies have shown significant improvement in outcomes with the use of prophylactic treatment, as well as apparent gains in health-related quality of life. However, recombinant clotting factors are also associated with relatively high cost. Using a lifetime Markov model, the cost-effectiveness of primary prophylaxis treatment was compared to on-demand treatment. This model is among the few that model long-term cost and effectiveness and is unique in that it takes into account the probability of inhibitor development, use of central venous access device (CVAD), and total bleeding risk including CNS and joint bleeds. Prophylactic treatment is assumed to be from birth until 16 years of age. Built in the model were also 5 health states: being alive, surgery, inhibitor development, disability and deceased. SUMMARY: From this model, cost-effectiveness estimations can be made for patients receiving on-demand treatment versus primary prophylaxis. Cost-effectiveness can vary by the frequencies of events between treatment arms, age where prophylaxis begins and ends, dose/frequency of factor VIII, cost of medications and key hospital-related events, and the probability of achieving specified clinical endpoints. CONCLUSIONS: The strengths and distinguishing characteristics of this model versus previously published hemophilia prophylaxis models include: long-term cost and effectiveness, probability of inhibitor development, use of CVAD, and CNS bleeds. There are a few study limitations related to the lack of data for model assumptions. Obtaining stronger evidence for these parameters may substantiate or potentially improve the model results.
